Answers are grounded in this paper and cite their sources.
Graphene oxide (GO) has great potential in biomedical applications due to its excellent photothermal effect and drug loading. Herein, dual-functionalized reduced nano-GO (nrGO-PEG/PEI) has been developed as a synergistic system of drug delivery and an NIR-light-absorbing agent. Covalently PEGylated nanographene oxide (nGO-PEG) was simultaneously reduced and PEIylated by bathing with polyethylenimine (PEI 1.8 kDa) solution in water at 80 °C for 2 h to obtain nrGO-PEG/PEI. nrGO-PEG/PEI exhibited low cytotoxicity and excellent dispersibility in physiological environments. Furthermore, nrGO-PEG/PEI had ∼20-fold increment in NIR absorption at 808 nm and ∼2.7-fold increment in doxorubicin (DOX) loading over unreduced nGO-PEG. Loaded DOX could be efficiently released from nrGO-PEG/PEI/DOX in an acidic environment (pH 5.0) and by NIR irradiation. In addition, nrGO-PEG/PEI could be rapidly encapsulated into cells and targeted to the nucleus region. In vitro and in vivo studies demonstrated the remarkable anticancer effects of nrGO-PEG/PEI/DOX with NIR laser irradiation. These results suggest that nrGO-PEG/PEI may be a novel drug delivery platform for controlling chemo-photothermal synergistic cancer therapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: